Answers are grounded in this paper and cite their sources.
Thyroid nodules are common, but most are benign. Concerning nodules undergo fine-needle aspiration (FNA) and are classified using The Bethesda System. Nodules with atypia of undetermined significance (AUS) [Bethesda III] have management options including surveillance, repeat FNA, molecular testing, and surgical evaluation. While molecular testing can reduce unnecessary surgeries, it is costly. This retrospective study assessed the feasibility of repeat FNA as a cost-effective alternative. We conducted a multi-institutional retrospective study of AUS nodules from five hospitals between September 1, 2018, and March 1, 2024. Only initial FNA cases were included; pediatric cases and those lost to follow up were excluded. Nodules were stratified by initial diagnostic choice (repeat FNA, molecular testing, surgical intervention). Clinical and ultrasonography findings were reviewed to determine associations with malignancy rates. Costs were estimated based on Medicare reimbursement rates. We identified 2,649 nodules that underwent FNA, with 199 interpreted as AUS. Of these, 131 met the criteria. Repeat FNA resulted in a benign diagnosis in 48.7% of cases and AUS in 35.9%. Costs were lowest for nodules undergoing repeat FNA. There was no significant difference in rates of surgical intervention or malignancy compared to molecular testing. ACR-TIRADS categories were not associated with malignancy rates. Only echogenic foci were significantly associated with malignancy (p=0.03). Repeat FNA resolved approximately 50% of cases, with no significant differences in malignancy or surgical intervention rates compared to molecular testing. Repeat FNA is the most cost-effective initial step for managing AUS nodules. Pre-biopsy ultrasonography had limited utility in stratifying malignancy risk for AUS nodules. • For thyroid fine needle aspirations diagnosed as atypia of undetermined significance (TBS III), repeat FNA provided a benign diagnosis in 48.7% of AUS cases and repeat AUS in 35.9% of cases. • Overall costs for diagnosis and management were lowest for nodules that underwent repeat FNA, based on Medicare reimbursement rates. • There were no significant differences in rates of surgical intervention or malignancy between nodules managed with repeat FNA and those that had molecular testing. • Pre-biopsy ultrasonography had limited utility in stratifying malignancy risk for AUS nodules, with only echogenic foci significantly associated with malignancy (p=0.03).
No takes yet. Share an insight, caveat, or question.
Dilli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: